Feature|Videos|March 27, 2024
Bioanalytical Methods to Optimize Drug Development: Hybrid LC-MS vs LBA
Drs Dawn Dufield and Dominic Warrino, KCAS Bioanalytical and Biomarker Services, share expertise on using Hybrid LC-MS versus LBA for bioanalytical analysis.
Selecting the right bioanalytical method to support qualitative and quantitative analysis requires flexibility and expertise from a CRO equipped to adapt to industry advancements.
Learn more:
- Understand when to use LC-MS, LBA or both.
- Learn why keeping LBA and Hybrid LC-MS in the forefront of your studies can result in big benefits.
- Understand the best method to optimize your drug development outcomes.
See the entire 45-minute deep-dive broken into an 11-part video series,
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Related Content
Trending on Pharmaceutical Technology
1
Drug Digest: Outsourcing Partnerships Fuel Global Biopharma Discovery and Scale-Up
2
Women in STEM: Early Phase Drug Development
3
Rare Disease Treatments: Navigating the Economics of Global Innovation
4
FDA Grants Priority Review For Pfizer’s Marstacimab for Hemophilia A or B
5